ProBioGen announced the closing of a master service agreement with Asahi Kasei Pharma. ProBioGen will use its proprietary technologies, like the CHO.RiGHT® cell line development platform and DirectedLuck™ transposase technology, to enable Asahi Kasei Pharma to advance their biologics pipeline.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“We are enchanted to work with Asahi Kasei Pharma on one of their key projects and are convinced that we can make a difference by applying our inventive technologies”, said Dr. Gabriele Schneider, Chief Business Officer at ProBioGen.
“After an intense selection process we decided to work with a very experienced and reliable partner as this is critical for the success of our project. We are impressed with ProBioGen's track record and their deep scientific insights, which led to a tailored development project,” Osamu Matsuzaki, Senior Executive Officer at Asahi Kasei Pharma said.